Nordic Life Science 1
ANDERS GÖRANSSON began his career as an accountan
t at Ernst & Young, and later worked as a consultant at McKinsey. From McKinsey, he moved to Amgen, where he led the Swedish operations before moving to Amgen’s European headquarters in Switzerland. He has held senior positions in several functions, such as sales and marketing, company integration, and most recently the responsibility for Amgen Innovation Europe. He has a Bachelor’s degree in business and economics from Uppsala University and an MBA from Suffolk University, USA. “It is with pride and energy that I look forward to taking on the role of CEO in Bactiguard. With Bactiguard’s technology and product portfolio, we can reduce healthcare-associated infections and reduce the need for healthcare worldwide. More and more large medical technology companies are starting to open their eyes to our unique technology,” says Göransson. 20 NORDICLIFESCIENCE.ORG ERIK SKULLERUD joins the company from Element Consulting, where he was co-founder and managing partner. Prior to establishing Element Consulting, he spent 25 years in the biopharma industry with increasing responsibilites in global sales and marketing management roles. He has launched numerous products in therapeutic areas such as oncology, hematology, cardiology, and nephrology and has business management exposure to EU, Asian and US markets. Skullerud has a BSc, Marketing, Finance and Management from Gothenburg Business School, University of Gothenburg and has been a Guest Lecturer, INSEAD MBA Program, Paris, France. Erik Skullerud will be based in the company’s office in Zug, Switzerland, splitting his time between Zug and Nordic Nanovector’s head office in Oslo, Norway. MARTIN OLIN previously served as CEO of Symphogen, which was acquired by Servier in 2020. Before joining Symphogen in 2012, Olin was a senior partner with SLS Invest, a Scandinavianbased healthcare-focused private equity fund. Previously, he held managerial positions in Novo Nordisk, including Finance Director, EMEA. Most recently he has served as Managing Partner of Nordic Eye. “I am very excited to join the company and look forward to working with the board and team to continue the progression of our lead candidate, bemcentinib, as well as the pipeline of drug candidates, through further clinical development and ultimately to the patients we believe will benefit from them,” says Olin. Following twelve years as CEO of BerGenBio, Richard Godfrey has decided to step down as CEO of the company with immediate effect to pursue other business interests. NILLE KLÆBEL joins Atlas Antibodies from her role as CEO Nordics at Philips, a position she has held since 2018. She joined Philips back in 2013. Previously she has held senior positions at GlaxoSmithKline, Sanofi and Novo Nordisk. “We are delighted to welcome Nille as the new CEO of Atlas Antibodies,” says Torben Jørgensen, Chair of the Board of Directors. “With her strong background in marketing and sales, and knowledge of the life sciences, pharma and healthcare industries, Nille is highly equipped to lead the next important steps in the development of Atlas Antibodies into a global life sciences company.” “I am thrilled to join Atlas Antibodies. The company is at a truly exciting stage right now, having completed two strategic acquisitions. I look forward to contributing to our continued journey of both organic as well as inorganic growth,” says Klæbel.